Macular degeneration drug approved

Share this article:

The Food and Drug Administration recently approved a drug for the treatment of the wet form of age-related macular degeneration. The medication is called Eylea. The medication is manufactured by Regeneron Pharmaceuticals. At $1,850 per injection, it costs $1000 less than Genentech's Lucentis. Macular degeneration is the leading cause of severe vision loss among residents in senior living settings.


Share this article:
close

Next Article in Products

More in Products

Aviv REIT offers public stock

Aviv REIT announced the public offering of 8 million shares of common stock at a public offering price of $24.10 per share.

NCAL unveils 2014 Assisted Living Week logo

NCAL unveils 2014 Assisted Living Week logo

The National Center for Assisted Living is encouraging communities to use the 2014 "The Magic of Music" logo to celebrate National Assisted Living Week.

New healthcare educational catalog available

New healthcare educational catalog available

Nasco has released its 2014-2015 Health Care Educational Materials catalog, which focuses on training with versatile medical procedure simulators.